Daniel DeAngelo, MD, PhD, discusses how TKIs have given patients with CML a full lifespan and what is being done to build on the incredible progress in this setting.
Daniel DeAngelo, MD, PhD
Advertisement
Articles by Daniel DeAngelo, MD, PhD
Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted triplet therapies.
As Leukemia and Lymphoma Awareness Month draws to a close, Daniel DeAngelo, MD, PhD, discusses the key trends in acute lymphoblastic leukemia treatment.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Expanding the Role of Immunotherapy in Lymphoma
2
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
3
CLL Treatment Enters a New Era of Targeted Combinations
4
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
5